Related Experiment Videos
Intra-articular steroids in pauciarticular juvenile chronic arthritis, type 1
R Hertzberger-ten Cate1, B C de Vries-van der Vlugt, L W van Suijlekom-Smit
1Indiana Children's Hospital, The Hague, The Netherlands.
Insights
Intra-articular steroid injections offer rapid relief for children with pauciarticular juvenile chronic arthritis (JCA), leading to long-lasting remission in many cases. This treatment effectively reduces joint swelling and pain with minimal adverse effects.
Area of Science:
- Pediatric Rheumatology
- Pharmacology
Background:
- Juvenile chronic arthritis (JCA) is a significant autoimmune condition in children.
- Pauciarticular JCA affects a limited number of joints, often impacting quality of life.
Purpose of the Study:
- To evaluate the efficacy and safety of intra-articular steroid injections in children with type 1 pauciarticular JCA.
- To determine the duration of remission and identify factors influencing treatment response.
Main Methods:
- A study involving 21 children diagnosed with type 1 pauciarticular JCA.
- Administration of intra-articular steroids into one or both knees.
- Monitoring for symptom relief, adverse reactions, and disease remission over a follow-up period.
Main Results:
- Beneficial effects, including reduced swelling and pain, were observed within 3 days post-injection.
- No significant adverse reactions were reported.
- Remission exceeding 6 months was achieved in 70% of treated knees, with 37% remaining inactive throughout follow-up.
- Treatment efficacy did not correlate with patient demographics, autoantibody status, or disease characteristics at onset.
Conclusions:
- Intra-articular corticosteroids provide prompt and effective symptom relief for pauciarticular JCA.
- This therapeutic approach can reduce the need for systemic treatments.
- Long-lasting remission is achievable in a significant proportion of pediatric patients.
Abstract:
The use of intra-articular steroids in one or both knees was evaluated in 21 children with type 1 pauciarticular juvenile chronic arthritis (JCA). The beneficial effect of the injection was noted within 3 days with no significant adverse reactions. Remission exceeding 6 months was seen in 70% of the knees and the arthritis remained inactive during the follow up period in 37%. The beneficial effect of the injection did not correlate with sex, age of onset or the presence of antinuclear antibodies or HLA-B27 antigen and there was no relationship with the size of involved joints at onset, the ESR at onset, or the presence of uveitis. Intra-articular corticosteroids in this type of JCA may provide prompt relief of swelling and pain and reduce the need for other forms of therapy. Remission was long lasting in the majority of the children.